Birt-Hogg-Dube syndrome: diagnosis and management

FH Menko, MAM van Steensel, S Giraud, L Friis-Hansen, S Richard, S Ungari, M Nordenskjold, TVO Hansen, J Solly, Eamonn Maher

    Research output: Contribution to journalReview article

    344 Citations (Scopus)


    Birt-Hogg-Dube syndrome (BHD) is an autosomal dominant condition characterised clinically by skin fibrofolliculomas, pulmonary cysts, spontaneous pneumothorax, and renal cancer. The condition is caused by germline mutations in the FLCN gene, which encodes folliculin; the function of this protein is largely unknown, although FLCN has been linked to the mTOR pathway. The availability of DNA-based diagnosis has allowed insight into the great variation in expression of FLCN, both within and between families. Patients can present with skin signs and also with pneumothorax or renal cancer. Preventive measures are aimed mainly at early diagnosis and treatment of renal cancer. This Review gives an overview of current diagnosis and management of BHD.
    Original languageEnglish
    Pages (from-to)1199-1206
    Number of pages8
    JournalThe Lancet Oncology
    Issue number12
    Publication statusPublished - 1 Dec 2009


    Dive into the research topics of 'Birt-Hogg-Dube syndrome: diagnosis and management'. Together they form a unique fingerprint.

    Cite this